QurCan Therapeutics
PrivateLast Round
Accelerator
Oct 5, 2022
Total Funding Raised
$6.15M
Company Overview
QurCan Therapeutics is a biotechnology company that develops a proprietary nanoparticle drug delivery platform for targeted therapeutics to treat cancer and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Advanced Materials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
QurCan Therapeutics Comparables
Compare QurCan Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nanite, Inc. | 86% | |
| CereCura Nanotherapeutics | 84% | |
| Nosis Bio | 79% |
QurCan Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Oct 5, 2022 | ||||
| Grant | Sep 1, 2022 | ||||
| Seed | May 17, 2021 | ||||
| Seed | Jan 28, 2020 | ||||
| Seed | Apr 8, 2019 | ||||
Grant | Mar 21, 2019 |
QurCan Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ontario Brain Institute | Grant, Seed |
| MEDTEQ+ | Seed |
| Mission BioCapital | Accelerator |
| National Research Council of Canada | Grant |
| Pfizer | Accelerator |
| FACIT | Seed |
| Ontario Centre of Innovation | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2022
$76K grant received from National Research Council of Canada.
- May 17, 2021
$3M round led by FACIT
Recent news
Latest coverage and updates
- is_developingSep 16, 2026
QurCan is developing genetic medicine therapeutics for diseases of the central and peripheral nervous systems on Sep 16th '26.
- partners_withSep 16, 2026
QurCan partnered with Lilly Group on Sep 15th '26.
- is_developingSep 15, 2026
QurCan is developing PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery on Sep 15th '26.
QurCan Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about QurCan Therapeutics's valuation, stock price, and market status.
Is QurCan Therapeutics a public or private company?
QurCan Therapeutics is a private company.
What is the current stock price of QurCan Therapeutics?
QurCan Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is QurCan Therapeutics worth (valuation)?
Valuation information for QurCan Therapeutics is not publicly available.
Can I buy QurCan Therapeutics stock?
QurCan Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was QurCan Therapeutics's last funding round?
Funding round information for QurCan Therapeutics is not publicly available.
Who are the main investors in QurCan Therapeutics?
Investor information for QurCan Therapeutics is not publicly disclosed.
Will QurCan Therapeutics IPO soon?
No public IPO plans have been announced for QurCan Therapeutics.
How can I track QurCan Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor QurCan Therapeutics's secondary market activity and sign up for updates.